$2.10 +0.07 (%) OncoGenex Pharmaceuticals Inc - NASDAQ

Dec. 22, 2014 | 12:50 PM

Partner Headlines

  1. US Stock Futures Edge Lower; Crude Oil Drops

    Benzinga | Dec. 16, 2014 | 07:03AM EST
  2. Events for the Week of Nov. 17-21, 2014

    Benzinga | Nov. 17, 2014 | 13:13PM EST
  3. George Soros Had A Mixed Day On The Market

    GuruFocus | Oct. 30, 2014 | 11:21AM EST
  4. OncoGenex Announces Update on Phase 3 ENSPIRIT Trial Evaluating Custirsen in Advanced Non-Small Cell Lung Cancer

    Benzinga | Aug. 21, 2014 | 16:02PM EST
  5. Stocks Hitting 52-Week Lows

    Benzinga | Jul. 29, 2014 | 10:26AM EST
  6. Morning Market Losers

    Benzinga | Apr. 28, 2014 | 09:51AM EST
  7. Benzinga's Top #PreMarket Losers

    Benzinga | Apr. 28, 2014 | 08:09AM EST
  8. UPDATE: Teva, Oncogenex Offer Top-Line Survival Results of Phase III SYNERGY Trial for Combo with First-Line Docetaxel, Prednisone, Primary End Point Was Not Reached

    Benzinga | Apr. 28, 2014 | 07:21AM EST
  9. UPDATE: CRT Capital Initiates Coverage on OncoGenex

    Benzinga | Feb. 27, 2014 | 11:06AM EST
  10. US Stock Futures Down Ahead Of Home Prices, Consumer Confidence Data

    Benzinga | Aug. 27, 2013 | 07:20AM EST
  11. OncoGenex Inititiates Rainier Clinical Trial Evaluating Apatorsen in Combination with ABRAXANE plus Gemcitabine

    Benzinga | Aug. 27, 2013 | 06:34AM EST
  12. OncoGenex Announces Initiation of Randomized Phase 2 "PACIFIC" Study of OGX-427 in Combo with Zytiga

    Benzinga | Dec. 19, 2012 | 02:33AM EST
  13. ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES Reports Operating Results (10-Q)

    GuruFocus | Nov. 8, 2012 | 11:36AM EST
  14. OncoGenex Announces Initiation Of A Phase 3 Trial For Custirsen In Advanced Non-Small Cell Lung Cancer

    Benzinga | Sep. 27, 2012 | 10:30AM EST
  15. ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES Reports Operating Results (10-Q)

    GuruFocus | Aug. 2, 2012 | 13:29PM EST
  16. Health Care Sector Wrap

    FoxBusiness | Jul. 19, 2012 | 10:52AM EST
  17. UPDATE: Bloom Burton Maintains Buy Rating, Lowers PT for OncoGenex

    Benzinga | May. 4, 2012 | 05:08AM EST
  18. UPDATE: Stifel NIcolaus Cuts Target on OncoGenex Pharmaceuticals to $35

    Benzinga | Mar. 9, 2012 | 06:15AM EST
  19. UPDATE: Bloom Burton Cuts PT to $24 on OncoGenex Pharmaceuticals

    Benzinga | Mar. 9, 2012 | 05:24AM EST
Trading Center